A
Alain C. Mita
Researcher at Cedars-Sinai Medical Center
Publications - 245
Citations - 9264
Alain C. Mita is an academic researcher from Cedars-Sinai Medical Center. The author has contributed to research in topics: Cancer & Tolerability. The author has an hindex of 44, co-authored 230 publications receiving 7877 citations. Previous affiliations of Alain C. Mita include University of Texas Health Science Center at San Antonio & University of Texas at San Antonio.
Papers
More filters
Journal ArticleDOI
Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
TL;DR: The multiple functions of Survivin in the regulation of apoptosis, the promotion of tumorigenesis, and the development of survivin inhibitors as a novel anticancer therapeutic strategy are reviewed.
Journal ArticleDOI
Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study.
Andrea B. Apolo,Jeffrey R. Infante,Ani Sarkis Balmanoukian,Manish R. Patel,Ding Wang,Karen Kelly,Anthony Mega,Carolyn D. Britten,Alain Ravaud,Alain C. Mita,Howard Safran,Thomas E. Stinchcombe,Marko Srdanov,Arnold B. Gelb,Michael Schlichting,Kevin M. Chin,James L. Gulley +16 more
TL;DR: Avelumab was well tolerated and associated with durable responses and prolonged survival in patients with refractory metastatic metastatic UC and PD-L1–associated clinical activity.
Journal ArticleDOI
Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors.
Alain C. Mita,Louis Denis,Eric K. Rowinsky,J. De-Bono,Andrew Goetz,Leonel Ochoa,Bahram Forouzesh,Muralidhar Beeram,Amita Patnaik,Kathleen Molpus,Dorothée Semiond,Michele Besenval,Anthony W. Tolcher +12 more
TL;DR: The general tolerability and encouraging antitumor activity in taxane-refractory patients warrant further evaluations of XRP6258.
Journal ArticleDOI
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
Josep Tabernero,Rastislav Bahleda,Rodrigo Dienstmann,Jeffrey R. Infante,Alain C. Mita,Antoine Italiano,Emiliano Calvo,Victor Moreno,Barbara Adamo,Anas Gazzah,Bob Zhong,Suso Platero,Johan W. Smit,Kim Stuyckens,Moitreyee Chatterjee-Kishore,Jordi Rodon,Vijay Gopal Reddy Peddareddigari,Feng R. Luo,Jean-Charles Soria +18 more
TL;DR: JNJ-42756493 administered at 10 mg on a 7- days-on/7-days-off schedule achieved exposures at which clinical responses were observed, demonstrated pharmacodynamic biomarker activity, and had a manageable safety profile.
Journal ArticleDOI
LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer
Masoud Tavazoie,Ilana Pollack,Raissa Tanqueco,Benjamin N. Ostendorf,Bernardo S. Reis,Foster C. Gonsalves,Isabel Kurth,Celia Andreu-Agullo,Mark L. Derbyshire,Jessica M. Posada,Shugaku Takeda,Kimia N. Tafreshian,Eric K. Rowinsky,Michael Szarek,Roger J. Waltzman,Elizabeth A. McMillan,Connie Zhao,Monica M. Mita,Alain C. Mita,Bartosz Chmielowski,Michael A. Postow,Antoni Ribas,Daniel Mucida,Sohail F. Tavazoie +23 more
TL;DR: The LXR/ApoE axis is implicate in the regulation of innate immune suppression and as a target for enhancing the efficacy of cancer immunotherapy in patients through genetic and pharmacological approaches.